Skeletal Muscles, Myokines and Glucose Metabolism MYOGLU

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

31 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-09-30

Study Completion Date

2012-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Normal glucose uptake and metabolism in skeletal muscles are essential to keep blood glucose within normal range and hence, insulin resistance (possibly mediated by inflammatory processes) in skeletal muscle is a major pathogenic factor in type 2 diabetes. Physical activity seems to be of essential importance in the prevention and treatment of type 2 diabetes. Myokines are proteins secreted from skeletal muscle that can execute important biological functions locally in the muscle (paracrine) or in other organs like the brain, heart and pancreas (endocrine). Evidence suggest that several interleukines and other cytokines are secreted by skeletal muscles. In the present project, the investigators will explore the relation between secreted myokines from muscle cells, insulin resistance and glucose metabolism before and after 12 weeks of exercise intervention. Subjects with normal as well as impaired glucose metabolism will be included in the study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Mechanisms of Resistance Exercise Training for Improved Muscle Insulin Sensitivity

NCT07128368

Resistance Training

NOT_YET_RECRUITING NA

Intensity of Exercise and Glucose Metabolism

NCT01649219

Prediabetes

UNKNOWN PHASE4

The Effects of Exercise of Secreted Factors From Muscle and Adipose Tissue

NCT02565823

Healthy

COMPLETED NA

MyoGene: Effects of Acute Exercise on (Myokine) Gene Expression in Human Skeletal Muscle

NCT01316731

Exercise Muscle Gene Expression +1 more

COMPLETED NA

Effects of Physical Exercise on Blood Glucose and Pain From the Musculoskeletal System in Patients With Type 2 Diabetes

NCT02366416

Type 2 Diabetes Mellitus

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hyperglycemia Normoglycemia Myokine

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Exercise in normoglycaemic individuals

Group Type EXPERIMENTAL

Exercise

Intervention Type OTHER

12 weeks of exercise; 4 times pr week

Exercise in hyperglycaemic individuals

Group Type EXPERIMENTAL

Exercise

Intervention Type OTHER

12 weeks of exercise; 4 times pr week

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Exercise

12 weeks of exercise; 4 times pr week

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male
* Age 40-65 years
* Nordic ethnicity
* Non-smoker

1. Either (participants with impaired glucose metabolism): Body Mass Index (BMI) 27-32 kg/m2 and abnormal glucose metabolism, defined as:

i. impaired fasting glucose (FPG ≥ 5.6 mmol/L) ii. impaired glucose tolerance (2 h PG ≥7.8 mmol/L) iii. type 2 diabetes (no medication, HbA1c ≤7.5%)
2. Or (controls): BMI 19-25 kg/m2 and normal glucose metabolism and no first degree relatives with type 2 diabetes.

9. Smoker
10. Any medical or other condition that in the judgment of the investigator would jeopardize the subject's safety or evaluation of the intervention for efficacy and safety
11. Exercising regularly (\>1 times pr week)

Exclusion Criteria

1. Subjects having type 1 diabetes or medically treated type 2 diabetes.
2. Systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 90 mmHg at screening
3. Significant hematological or renal disease or chronic renal impairment, GFR\< 50 ml/min.
4. Significant liver disease or ALAT \>3x UNL.
5. Chronic inflammatory disease in active phase or long-term use of corticosteroids last 3 months.
6. Use of anti-diabetic agents, lipid lowering drugs, antihypertensive medication, ASA or any other drug not deemed suitable by the study physician.
7. Mental condition (psychiatric or organic cerebral disease), drug or alcohol abuse rendering the subject unable to understand the nature, scope and possible consequences of the study.

Minimum Eligible Age

40 Years

Maximum Eligible Age

65 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes